NCT05894824 2025-07-11T-Dxd in Combination With Ramucirumab as HER2 Low Gastric or Gastroesophageal Junction (GEJ) AdenocarcinomaYonsei UniversityPhase 1/2 Recruiting58 enrolled
NCT02999295 2019-08-21A Phase 1/2 Study of Ramucirumab Plus Nivolumab in Participants With Gastric or GEJ CancerNational Cancer Center, JapanPhase 1/2 Completed46 enrolled